Former mining research organisation, CRCMining, a longstanding client of Shelston IP, has partnered with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) to create Mining3. The partnership brings together the substantial mining research capabilities of each organisation to create a truly world leading mining research entity. Mining3 integrates CSIRO’s Mineral Resources group with CRCMining’s
Dr Serena White, Shelston IP Patent Attorney and recent expat to Australia, reflects on things we love about working in Australia. To read the full article, which appeared in the November 2016 edition of ‘CIPA Journal’ please click here.
Ownership and licensing arrangements relating to an Australian patent can have significant implications in infringement and revocation proceedings. Recent decisions delivered by the Federal Court of Australia have highlighted the need for patentees to consider carefully and formalise their chain of title and exclusive licensing arrangements, or else risk losing their patents and/or the markets
The Intellectual Property Office of New Zealand (IPONZ) has announced that it will be closed, firstly, on Monday, 14 November – and now, Tuesday, 15 November 2016. Any New Zealand deadlines falling on either day extend automatically to the next day that IPONZ is open; best estimates are that this will be Wednesday, 16 November
In the recent case of 3 Florinians Pty Ltd v PYT Enterprise Pty Ltd  FCA 1077 (September 5, 2016), the Federal Court granted an interlocutory injunction to Florinians, the owner of the LITTLE GREEK TAVERNA trademark, against co-respondents PYT Enterprise Pty Ltd and its licensee Adamaris Pty Ltd restraining use of the LITTLE GREEK
Recently, we reported on an Australian Patent Office decision – Arrowhead Research Corporation  APO 70 (13 October 2016) (Arrowhead decision), which confirmed that gene-based pharmaceuticals, namely interfering RNA (iRNA) compositions, do represent patentable subject matter in Australia. This decision sets a significant legal precedent in relation to the patentability of iRNA compositions, which were